A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer

Trial Profile

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Ramucirumab (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RELAY
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 Oct 2017 Results (data cut off: 31 May 2017, n=14) from part A (phase Ib) of the study assessing safety and tolerability, presented at the 18th World Conference on Lung Cancer.
    • 02 Sep 2017 Planned End Date changed from 1 Dec 2019 to 1 Aug 2021.
    • 13 Jun 2017 Planned End Date changed from 1 Apr 2020 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top